Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance

• Published in: Clinical endocrinology (Oxford) 2005-01, Vol.62 (1), p.85-91
• Main Authors: Hung, Yi-Jen, Hsieh, Chang-Hsun, Pei, Dee, Kuo, Shi-Wen, Lee, Jiunn-Tay, Wu, Ling-Yi, He, Chih-Tsueng, Lee, Chien Hsing, Fan, Sandra Chyi, Sheu, Wayne Huey-Herng
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological and medical sciences; Blood Glucose - analysis; C-Peptide - analysis; Chi-Square Distribution; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Fundamental and applied biological sciences. Psychology; Glucose Tolerance Test; Humans; Hypoglycemic Agents - therapeutic use; Insulin - blood; Insulin Resistance; Male; Medical sciences; Middle Aged; Sex Factors; Single-Blind Method; Thiazolidinediones - therapeutic use; Treatment Outcome; Vertebrates: endocrinology
• ISSN: 0300-0664; 1365-2265
• DOI: 10.1111/j.1365-2265.2004.02178.x

Summary Objective  This study was designed to evaluate the effects of rosiglitazone (ROS) on insulin sensitivity, β‐cell function, and glycaemic response to glucose challenge and meal in subjects with impaired glucose tolerance (IGT). Methods  Thirty patients with IGT (ages between 30 and 75 years and BMI (body mass index) ≤ 27 kg/m2) were randomly assigned to receive either placebo (n = 15) or ROS (4 mg/day) (n = 15). All participants underwent a 75‐g oral glucose tolerance test (OGTT), meal test, and frequently sampled intravenous glucose tolerance test (FSIGT) before and after the 12‐week treatment. Results  After 12 weeks of ROS treatment, there were significant increases in total cholesterol (TC) (4·25 ± 0·22 vs 4·80 ± 0·17 mmol/l, P